Atea Pharmaceuticals, Inc. — Director's Dealing 2026

Feb 3, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2026-01-31

Reporting Person: Sommadossi Jean-Pierre (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-01-31	Common Stock	M	272983	—	Acquired	573923	Direct
2026-01-31	Common Stock	F	106093	$4.24	Disposed	467830	Direct
2026-02-03	Common Stock	M	300000	$1.24	Acquired	767830	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-31	Restricted Stock Units	$	M	173466	Disposed		Common Stock (173466)	Direct
2026-01-31	Restricted Stock Units	$	M	99517	Disposed		Common Stock (99517)	Direct
2026-02-03	Stock Option (Right to Buy)	$1.24	M	300000	Disposed	2026-12-08	Common Stock (300000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5866025	Indirect

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: The original grant of 520,400 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.

F3: Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.

F4: Reflected one (1) share correction due to prior administrative rounding error with respect to RSU vesting in 2026.

F5: The option is fully vested and exercisable.